Results 251 to 260 of about 320,703 (320)

Use of pegylated interferon in hypereosinophilic syndrome

Leukemia Research, 2012
Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients.
Joseph H, Butterfield, Catherine R, Weiler   +1 more
openaire   +2 more sources

Sylatron: A Pegylated Interferon for Use in Melanoma

Annals of Pharmacotherapy, 2012
OBJECTIVE: To review the currently available literature on peginterferon alfa-2b (pegIFN [Sylatron]), including its role in therapy and toxicity for adjuvant treatment of locally advanced melanoma. DATA SOURCES: A literature search was performed of PubMed and the American Society of Clinical Oncology abstracts from 1976 to February 2012, using the ...
Jai N, Patel, Christine M, Walko
openaire   +2 more sources

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C

Journal of Controlled Release, 2001
Poly(ethyleneglycol) or PEG has proven to be of great value for a range of biomedical applications. A review the properties of PEG that lead to these applications is reported. Emphasis is placed on pharmaceutical uses of PEG--proteins, with specific discussion of the attributes of PEGylated alpha-interferon for treatment of hepatitis C.
A, Kozlowski, J M, Harris
openaire   +2 more sources

Pharmacokinetics of pegylated interferons: What is misleading?

Digestive and Liver Disease, 2004
Available pegylated interferon (PEG-IFN) products confer enhanced therapeutic efficacy when compared with their IFN counterparts, and the added convenience of once-weekly dosing with no novel toxicities. PEG optimises the action of the IFNs by decreasing clearance rates, thereby allowing serum concentrations to remain constant over the dosing period ...
openaire   +3 more sources

Differential Antiviral Effects of Pegylated Interferon-α2a and Pegylated Interferon-α2b in Chronic Hepatitis C

Clinical Drug Investigation, 2014
Pegylated interferon (peg-IFN)-α2a and -α2b show different pharmacokinetic properties but are used interchangeably for hepatitis C treatment in traditional dual combinations and with newer agents. We assessed whether peg-IFN antiviral effects vary with peg-IFN subtype, affecting viral response in a differential manner.Chronic hepatitis C patients ...
DURANTE MANGONI, Emanuele, Parrella A, Iossa D, Andini R, Molaro R, Battimelli C, Sodano G, UTILI, Riccardo   +7 more
openaire   +3 more sources

Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta

International Immunopharmacology, 2018
Because PEGylated molecules exhibit different physicochemical properties from those of the parent molecules, PEGylated interferonβ-1a (pegIFNβ-1a) may be able to be used with retained bioactivity in Multiple Sclerosis (MS) patients who have previously developed neutralizing antibodies (NABs) to recombinant interferonβ (rIFNβ).
Francesca, Gilli, Adrianna L, De La Torre, Darlene B, Royce, Andrew R, Pachner   +3 more
openaire   +2 more sources

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders†‡

Hepatology, 2009
Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).
Vinod K, Rustgi, William M, Lee, Eric, Lawitz, Stuart C, Gordon, Nezam, Afdhal, Fred, Poordad, Herbert L, Bonkovsky, Leif, Bengtsson, Gurudatt, Chandorkar, Matthew, Harding, Lindsay, McNair, Molly, Aalyson, John, Alam, Robert, Kauffman, Shahin, Gharakhanian, John G, McHutchison   +15 more
openaire   +2 more sources

Early virologic response with pegylated interferons

Digestive and Liver Disease, 2004
Recently, 12-week evaluation of viral response has been recommended as a means of reducing antiviral treatment morbidity and costs. The development of early stopping rules relies on an important assumption: rules must minimise discontinuation of treatment in patients who might ultimately respond after completion of the full course of therapy ...
openaire   +2 more sources

Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C

Drugs, 2013
Results of trials and meta-analyses comparing pegylated interferon (PEG-IFN)-α2a and PEG-IFN-α2b for the treatment of chronic hepatitis C are conflicting.Our objective was to determine which PEG-IFN (α2a or α2b), in association with ribavirin, is the most effective for the treatment of chronic hepatitis C by performing an updated meta-analysis.MEDLINE (
Nicolas, Flori, Natalie, Funakoshi, Yohan, Duny, Jean-Christophe, Valats, Michael, Bismuth, Dimitri, Christophorou, Jean-Pierre, Daurès, Pierre, Blanc   +7 more
openaire   +2 more sources

PEGylation of Interferon-β-1a

CNS Drugs, 2012
Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are ...
Bernd C, Kieseier, Peter A, Calabresi
openaire   +2 more sources